Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$26.31M, compared with -$13.28M a year earlier. Trailing-twelve-month EBITDA was -$67.53M.

Context

  • EBITDA amounted to 93.4% of revenue in FY2025, up 37.4 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of -$80.43M (-28.2%) for the fiscal year ending Dec 2026, a slowdown from the +18.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.31M-30.6% QoQ
Last fiscal yearDec 2025
-$62.76M+18.9% YoY
LTMMar 2026
-$67.53M-3.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.2%-229.8%-131.7 pp
1 year+18.9%-28.2%-47.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(62.76M) USD
Year-over-year change
+18.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.7% is the 5th highest of 10, against a peer median of -30.1%.
  • EBITDA amounts to 148.9% of revenue for ARCT, versus a peer median of 201.5%.
ARCT Competitors
EBITDA for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.85M USD+305.5%—84.0%
NVAXNovavax, Inc.LTM Mar 2026-$42.13M USD-107.6%—7.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$53.46M USD-44.4%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$81.94M USD+12.2%——
VALNValneva SELTM Mar 2026-€90.14M EUR-119.6%—57.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$179.89M USD-30.1%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$194.47M USD+21.0%——
VIRVir Biotechnology, Inc.LTM Mar 2026-$438.52M USD+24.4%—669.6%
Peer median (excluding ARCT) —-30.1%—201.5%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.